V. Daurat

发表

Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study.

Sylvie Chevret, Philippe Ravaud, Geneviève Chêne, 2011, Contemporary clinical trials.

Determination of total cysteamine in human serum by a high-performance liquid chromatography with fluorescence detection.

P. Prognon, V. Daurat, D. Pradeau, 1998, Journal of pharmaceutical and biomedical analysis.

Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial

P. Marcellin, D. Dhumeaux, D. Samuel, 2003, Journal of viral hepatitis.

A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers.

P. Chaumet‐Riffaud, C. Funck-Brentano, V. Daurat, 1999, British journal of clinical pharmacology.

Reinforced regiment of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomized trial

S. Chevret, C. Chastang, P. Chaumet‐Riffaud, 1998 .

Immunodulator activity of very low doses of thymulin in mice

V. Daurat, M. Bastide, A. Pèlegrin, 1987 .

A short induction regimen of interferon‐α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial

S. Chevret, C. Chastang, M. Vidaud, 1999 .

Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa

S. Chevret, P. Chaumet‐Riffaud, F. Degos, 1999 .

Activity and chronopharmacology of very low doses of physiological immune inducers.

V. Daurat, M. Bastide, M. Doucet-Jaboeuf, 1985, Immunology today.

des promotions industrielles promotions institutionnelles

J. Ménard, V. Daurat, 2006 .

Immunomodulatory activity of low doses of interferon alpha,beta in mice.

V. Daurat, M. Bastide, P. Dorfman, 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.